viewParadigm Biopharmaceuticals Ltd

Paradigm Biopharmaceuticals strengthens team with additional clinical and commercial expertise

The company is preparing for phase-3 trials in both Osteoarthritis (OA) and Mucopolysaccharidosis (MPS).

Paradigm Biopharmaceuticals Ltd - Paradigm Biopharmaceuticals add to clinical and commercial expertise with new appointments to the team
Paradigm is an Australian biopharmaceutical company focused on repurposing the drug pentosan polysulphate sodium (PPS) for the treatment of inflammation.

Paradigm Biopharmaceuticals Ltd (ASX:PAR) has added to the clinical and commercial development expertise of its management team through the appointments of Jeannie Joughlin and Michael Imperiale.

The appointments add considerable experience and strengthen the team as the company prepares phase-3 trials in Oseoarthiritis and Mucopolyaccharidosis.

“Exciting time for Paradigm”

Chief executive officer Paul Rennie said: “It is a very exciting time for Paradigm and to add two highly experienced staff members whose diverse skills will complement the current Paradigm team is very pleasing.

“Both Jeannie and Michael will play integral roles as Paradigm continues to prepare for multiple clinical trials, 2 x Phase 3 clinical trials in Osteoarthritis, one Phase 2 in MPS-I and one Phase 3 in MPS-VI.

“Paradigm has an ambitious clinical development program and having two highly experienced executives join our team, at this time, further prepares us for timely execution of these programs”.

Experienced biopharmaceutical leader

Dr Joughlin has been appointed to the role of chief operating officer after holding senior executive roles and during almost nine years in the US these roles were with Enable Injections and CSL Behring.

She is an experienced biopharmaceutical and medical device leader with more than 20 years in global biopharmaceutical companies and start-up environments.

Upon her return to Australia in early 2019, she provided ongoing leadership support to Enable Injections, joined an ASX-listed company as non-executive director and provided guidance as a principal commercial advisor to Australian biotechnology and medical technology companies.

Her responsibilities and experience have included extensive post-doctoral research, clinical trial management, brand management, licensing and business development, team leadership, strategic planning, capital raising, as well as partner relationship and alliance management.

While at CSL Behring, she was involved with the in-licensing of Tramadol from Grunenthal into the Australian market.

International drug development experience

Dr Imperiale has been appointed to the role of global head of safety with more than 25 years’ of international drug development experience in the biotechnology and pharmaceutical industry.

He will also head up Paradigm’s MPS IV clinical program with his experience in Lysosomal Storage Diseases.

Previously, Imperiale worked at Nektar Therapeutics, where he led the development of their Immuno-Oncology and Pain programs.

Prior to joining Nektar, he was the global medical lead in medical affairs at BioMarin where he managed the Lysosomal Storage disease and PKU franchises.

He also held the vice president of clinical research position at Talon Therapeutics (Hana Biosciences), where he successfully developed Marquibo® for adult Acute Lymphocytic Leukemia (ALL).

Inaugural COO thanked

In welcoming Joughlin to the COO role, Rennie also paid tribute to Dr Claire Kaufman, Paradigm’s inaugural COO.

He said: “Claire’s leadership and experience was pivotal in both our early start-up phase and later as the clinical program developed. We wish her well in her future endeavours”.

Quick facts: Paradigm Biopharmaceuticals Ltd

Price: 2.87 AUD

Market: ASX
Market Cap: $651.38 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Paradigm Biopharmaceuticals Ltd named herein, including the promotion by the Company of Paradigm Biopharmaceuticals Ltd in any Content on the...


3 min read